{
  "docId": "019de076-b3a4-71cc-8183-985590ab9557",
  "docSlug": "2fc842fd1dad3dbfa44767764fb3543f",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 21 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 21,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a wave-based metaphor to represent sequential growth phases of partner programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b3a4-71cc-8183-985590ab9557/12",
  "deckHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557",
  "deckJsonHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json",
  "deckAnchorHref": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.18,
        "x": 0.59,
        "y": 0.00175
      },
      "kind": "list",
      "text": "Fourth Wave: 20+ Additional Preclinical Partner Programs, Launch 2030+, Indications: Solid Tumors, Autoimmune, Neurodegenerative, Genetic, Lymphoma/Leukemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d2838ac-7be7-4900-bc04-8e7020599f76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.18,
        "x": 0.21,
        "y": 0.00175
      },
      "kind": "list",
      "text": "Second Wave: 7 Potential Approved Partner Programs, Launch 2025-2027, SPL Partner A Programs, Caribou, Editas, Precision Bio, Vor, Invios, Indications: Lymphoma/Leukemia, Solid Tumors, Sickle Cell, Beta-Thalassemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52868d2f-7c7d-426c-9cb2-5b2f943b4861",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.18,
        "x": 0.4,
        "y": 0.00175
      },
      "kind": "list",
      "text": "Third Wave: 8 Potential Approved Partner Programs, Launch 2028-2030, Undisclosed, Indications: Solid Tumors, Lymphoma/Leukemia, Multiple Myeloma, Sickle Cell, Beta-Thalassemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59e4b86f-9e89-41e8-8407-74a6d99937cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.18,
        "x": 0.02,
        "y": 0.00175
      },
      "kind": "list",
      "text": "First Wave: 1 Potential Approved Partner Program, Launch 2024, Vertex's Exa-Cel, Sickle Cell Disease, Beta-Thalassemia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cc6c137-bf2f-4fec-abc7-050d1ebb5e78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.18,
        "x": 0.78,
        "y": 0.00175
      },
      "kind": "list",
      "text": "Fifth Wave: Additional Licensed Programs and New Partnerships Signed, Launch 2032+",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7843289-5ba8-4419-afd9-1a830d00a09e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.07,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma as of August 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d57f55fc-4677-4eed-b90d-40c3a65c705d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "MaxCyte Partnerships – Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d68a1e06-ad62-417b-8130-65aee59f5b55",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "dbd7dfb9-ca59-48ae-9667-311a2ee078df",
      "evidence": "Sequential waves representing future growth phases",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Traction is showcased from pages 7-14.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887",
      "evidence": "The traction section highlights the benefits of partnering with MaxCyte.",
      "position": 1,
      "objective": "What are the benefits of partnering with MaxCyte?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}